Додайте свій проект безкоштовно і почніть отримувати пропозиції від фрілансерів-виконавців вже через хвилини після публікації!

перевод с английского на русский

закрито без виконання


BACKGROUND: Although treatment for multiple myeloma (MM) has considerably improved in the past decade, MM continues to be an incurable hematological malignancy that causes most patients to eventually relapse and die from their illness. Thus, the identification of effective salvage strategies remains a priority.

METHODS: In this trial, the authors evaluated the safety and efficacy of bortezomib and dexamethasone [V: on days 1 and 15 (1.3 mg/ mq); D: on days 1-2 and 15-16, every 28-day cycle until progression (20 mg/d)] as maintenance therapy (MT) in patients with advanced MM who responded to salvage therapy that used a bortezomib-containing regimen. RESULTS: Forty-nine MM patients were enrolled in this study between October of 2004 and April of 2008. All patients who were included in this study were responsive to a prior salvage therapy with bortezomib and had a measurable disease. The bortezomib and dexamethasone MT improved the quality of responses to complete remission in 4 patients and very good partial response in 3 patients. In addition, 10 patients experienced at least a 50% improvement in their symptoms. The median time to progression (TTP) was 16 months with a progression-free survival of 61% after 1 year. The overall response after 1 year was 76%, and the cumulative incidence of death due to disease progression, which was adjusted for competitive risk events, was 14%. Non-dose-limiting toxicities included neuropathy (predominantly grade 1), herpes zoster reactivation, pneumonia, and gastrointestinal affections (constipation and diarrhea). Three patients developed grade 2 neuropathy, which required a bortezomib dose reduction to 1.0 mg/mq. No grade 3 or 4 toxicities were recorded. CONCLUSIONS: The use of bortezomib and dexamethasone as MT in advanced MM was effective and well tolerated. The twice-monthly bortezomib infusion appeared to reduce the incidence of grade 3 and 4 neuropathies in comparison to similar experiences in other settings. Cancer 2011;117:1884– 90. VC 2010 American Cancer Society. KEYWORDS: bortezomib, dexamethasone, myeloma, relapsed, refractory.



  1.  1471 
    84   47   0

    1 деньприхована
    Андрей Олейник перевірений 

    100 руб.=1000 зн., обращайся!

    Україна Херсон | 13 січня 2017 |
  2.  3149 
       167   0

    1 деньприхована

    Готов выполнить сегодня.

    Україна Львів | 13 січня 2017 |
  3. 1 деньприхована
    Yuliana Rodina
     477   19   0

    Доброе утро. Буду рада сотрудничеству! 80 грн- 1000 зн.б.п.

    Україна Україна | 13 січня 2017 |
  4. 1 деньприхована
    Lilit Amiryan
     411   7   0

    Профессиональный переводчик с опытом работы уже более 15 лет. Только ручной адаптированный перевод.
    Никогда не пользуюсь Google или каким-либо другим видом машинного перевода.
    Примеры некоторых работ смотрите в портфолио на моей странице.
    180 рублей/ 1800 зсп. Вам нужен перевод или рерайт?

    Грамотность, аккуратность и пунктуальность гарантирую.

    Skype: VAHE LILIT AMIRYAN
    E-mail: [email protected]

    Вірменія Yerevan | 13 січня 2017 |
  1.  фрілансер більше не працює на сервісі

Замовник
Danara ADN
Казахстан Астана  3   0
Проект опублікований
13 січня 2017
162 перегляди
Мітки